celecoxib has been researched along with oxadiazoles in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Boschi, D; Cena, C; Del Grosso, E; Di Stilo, A; Fruttero, R; Gasco, A; Lazzarato, L; Moro, S | 1 |
| Eltze, M; Grebe, T; Hatzelmann, A; Klein, T; Kömhoff, M | 1 |
| Amanzadeh, A; Amini, M; Irian, S; Nabiuni, M; Norouzi, M; Norouzi, S; Salimi, M | 1 |
| Abdelhamid, AA; Al-Sanea, MM; Gomaa, HAM; Mohamed, MFA; Moustafa, AH; Youssif, BGM | 1 |
| Abuo-Rahma, GEA; Allam, RM; El Subbagh, HI; El-Gamal, DA; Marzouk, AA; Mohamed, MFA; Moustafa, AH; Nafady, A | 1 |
| A A Abd El-Wahab, H; Abdel-Fattah, HA; E A Hassan, A; Ghanim, AM; Hamoud, MMS; Osman, NA; Rezq, S; Romero, DG | 1 |
6 other study(ies) available for celecoxib and oxadiazoles
| Article | Year |
|---|---|
The furoxan system: design of selective nitric oxide (NO) donor inhibitors of COX-2 endowed with anti-aggregatory and vasodilating activities.
Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Design; Humans; Lactones; Models, Molecular; Molecular Structure; Nitric Oxide Donors; Oxadiazoles; Platelet Aggregation Inhibitors; Pyrazoles; Sulfonamides; Sulfones; Vasodilator Agents | 2005 |
Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta; Celecoxib; Coronary Vessels; Cyclic GMP; Endothelium, Vascular; Guanylate Cyclase; Guinea Pigs; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Donors; Nitric Oxide Synthase; Nitroprusside; Oxadiazoles; Perfusion; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Purinones; Pyrazoles; Quinoxalines; Rats; Regional Blood Flow; Signal Transduction; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2007 |
Two COX-2 inhibitors induce apoptosis in human erythroleukemia K562cells by modulating NF-κB and FHC pathways.
Topics: Apoptosis; Celecoxib; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Erythroblastic, Acute; NF-kappa B; Oxadiazoles; Proto-Oncogene Proteins c-myc; Signal Transduction | 2016 |
Novel aryl carboximidamide and 3-aryl-1,2,4-oxadiazole analogues of naproxen as dual selective COX-2/15-LOX inhibitors: Design, synthesis and docking studies.
Topics: Animals; Cattle; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Design; Glycine max; Humans; Lipoxygenase Inhibitors; Lymphocytes; Mice; Molecular Docking Simulation; Naproxen; Nitric Oxide Donors; Oxadiazoles | 2019 |
Design, synthesis and molecular modeling of novel aryl carboximidamides and 3-aryl-1,2,4-oxadiazoles derived from indomethacin as potent anti-inflammatory iNOS/PGE2 inhibitors.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Dinoprostone; Dose-Response Relationship, Drug; Edema; Enzyme Inhibitors; Humans; Indomethacin; Lipopolysaccharides; Male; Mice; Molecular Docking Simulation; Molecular Structure; Nitric Oxide; Nitric Oxide Synthase Type II; Oxadiazoles; Oximes; Rats; RAW 264.7 Cells | 2020 |
Design and Synthesis of Novel 1,3,4-Oxadiazole and 1,2,4-Triazole Derivatives as Cyclooxygenase-2 Inhibitors with Anti-inflammatory and Antioxidant activity in LPS-stimulated RAW264.7 Macrophages.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Design; Interleukin-6; Lipopolysaccharides; Macrophages; Molecular Docking Simulation; Nitric Oxide; Oxadiazoles; Reactive Oxygen Species; Structure-Activity Relationship; Triazoles | 2022 |